6. Bibliografía

-Williams HC, Dellavalle RP, Garner S. Acne vulgaris. Lancet. 2012; 379(9813):361-72.

-Kurokawa I, Layton AM, Ogawa R. Updated treatment for acne: targeted therapy based on pathogenesis. Dermatol Ther (Heidelb). 2021; 11(4):1129-39.

-Tan JKL, Stein Gold LF, Alexis AF, Harper JC. Current Concepts in Acne Pathogenesis: Pathways to Inflammation. Semin Cutan Med Surg. 2018; 37(3S):S60-S62.

-Kircik LH. Advances in the Understanding of the Pathogenesis of Inflammatory Acne. J Drugs Dermatol. 2016; 15(1 Suppl 1):s7-10.

-Tan JK, Bhate K. A global perspective on the epidemiology of acne. Br J Dermatol. 2015; 172 Suppl 1:3-12

-Zouboulis CC. Acne vulgaris. Hautarzt. 2014; 65:733-47.

-Bhate K, Williams HC. Epidemiology of acne vulgaris. Br J Dermatol. 2013; 168:474-85.

-Del Rosso JQ, Kircik LH, Stein Gold L, et al. Androgens, androgen receptors, and the skin: from the laboratory to the clinic with emphasis on clinical and therapeutic implications. J Drugs Dermatol. 2020;19(3):30-5.

-Cao K, Liu Y, Liang N, et al. Fatty acid profiling in facial sebum and erythrocytes from adult patients with moderate acne. Front Physiol. 2022; 13:921866.

-Rosette C, Agan FJ, Mazzetti A, et al. Cortexolone 17α-propionate (clascoterone) is a novel androgen receptor antagonist that inhibits production of lipids and inflammatory cytokines from sebocytes in vitro. J Drugs Dermatol. 2019; 18(5):412-8.

-Salemi M, Dadkhahfar S, Tehranchinia Z, Razzaghi Z, Ghalamkarpour F. Evaluating the Association Between Acne Vulgaris and Diet: An Exploratory Study on Patient Beliefs and Perceptions. J Cosmet Dermatol. 2025; 24(7):e70285.

–Mahmood SN, Bowe WP. Diet and acne update: carbohydrates emerge as the main culprit. J Drugs Dermatol. 2014

-Dai R, Hua W, Chen W, Xiong L. Li L. The effect of milk consumption on acne: a meta-analysis of observational studies. J Eur Acad Dermatol Venereol. 2018. doi: 10.1111/jdv.15204.

-Akpinar Kara Y, Ozdemir D. Evaluation of food consumption in patients with acne vulgaris and its relationship with acne severity. J Cosmet Dermatol. 2019. doi: 10.1111/jocd.13255

-Conforti C, Agozzino M, Emendato G, Fai A, Fichera F, Marangi GF, Neagu N, Pellacani G, Persichetti P, Segreto F, Zalaudek I, Dianzani C. Acne and diet: a review. Int J Dermatol. 2022; 61(8):930-934.

-Meixiong J, Ricco C, Vasavda C, Ho BK. Diet and acne: A systematic review. JAAD Int. 2022; 7:95-112).

-Holzmann R, Shakery K. Postadolescent acne in females. Skin Pharmacol Physiol. 2014;27 Suppl 1:3-8.

-Chanyachailert P, Chularojanamontri L, Chantrapanichkul P, Tuchinda P, Wongwananuruk T, Sardod P, Kulthanan K. Adult female acne: Clinical characteristics and factors significantly associated with polycystic ovary syndrome. Australas J Dermatol. 2021; 62(4):e532-e538.

-Zaenglein AL, Pathy AL, Schlosser BJ, et al. Guidelines of care for the management of acne vulgaris. J Am Acad Dermatol. 2016; 74(5):945-73.

-Dreno B, Bagatin E, Blume-Peytavi U, Rocha M, Gollnick H. Female type of adult acne: Physiological and psychological considerations and management. J Dtsch Dermatol Ges. 2018; 16(10):1185-1194.

-Bagatin E, Rocha MADD, Freitas THP, Costa CS. Treatment challenges in adult female acne and future directions. Expert Rev Clin Pharmacol. 2021; 14(6):687-701.

-Dréno B, Nguyen JM, Hainaut E, Machet L, Leccia MT, Beneton N, Claudel JP, Célérier P, Le Moigne M, Le Naour S, Vrignaud F, Poinas A, Dert C, Boisrobert A, Flet L, Korner S, Khammari A. Efficacy of Spironolactone Compared with Doxycycline in Moderate Acne in Adult Females: Results of the Multicentre, Controlled, Randomized, Double-blind Prospective and Parallel Female Acne Spironolactone vs doxyCycline Efficacy (FASCE) Study. Acta Derm Venereol. 2024; 104:adv26002.

-Lipson J. Adult Female Acne: Managing the Hormones. Skin Therapy Lett. 2024; 29(4):5-7).

-Meena AK, Mendiratta V, Goyal R, Bisherwal K, Yadav V, Prasadh V. Biochemical and hormonal abnormalities in adult female acne. J Cosmet Dermatol. 2023; 22(4):1392-1399.

-Chanyachailert P, Chularojanamontri L, Chantrapanichkul P, Tuchinda P, Wongwananuruk T, Sardod P, Kulthanan K. Adult female acne: Clinical characteristics and factors significantly associated with polycystic ovary syndrome. Australas J Dermatol. 2021; 62(4):e532-e538.

-Sardana K, Muddebihal A, Sehrawat M, Bansal P, Khurana A. An updated clinico-investigative approach to diagnosis of cutaneous hyperandrogenism in relation to adult female acne, female pattern alopecia & hirsutism a primer for dermatologists. Expert Rev Endocrinol Metab. 2024; 19(2):111-128).

-Knutsen-Larson S, Dawson AL, Dunnick CA, Dellavalle RP. Acne vulgaris: pathogenesis, treatment, and needs assessment. Dermatol Clin. 2012; 30:99-106.

-Tan J, Frey MP, Knezevic S, Poulin Y, Lynde CW, Gulliver WP, Gupta AK, Sebaldt RJ, Thomas DR, Sapra S. The Relationship Between Dermatologist- and Patient-Reported Acne Severity Measures and Treatment Recommendations. J Cutan Med Surg. 2015; 19:464-9.

-Lain E, Day D, Harper J, Guenin E. Tretinoin 0.05% Lotion for the Once-Daily Treatment of Moderate-to-Severe Acne Vulgaris: Impact of Gender and Race on Efficacy and Safety. J Drugs Dermatol. 2019; 18:1128-1138.

-Gollnick HP. From new findings in acne pathogenesis to new approaches in treatment. J Eur Acad Dermatol Venereol. 2015; 29 Suppl 5:1-7.

-Nast A, Dréno B, Bettoli V, Degitz K, Erdmann R, Finlay AY, Ganceviciene R, Haedersdal M, Layton A, López-Estebaranz JL, Ochsendorf F, Oprica C, Rosumeck S,  Rzany B, Sammain A, Simonart T, Veien NK, Zivković MV, Zouboulis CC, Gollnick H; European Dermatology Forum. European evidence-based (S3) guidelines for the treatment of acne. J Eur Acad Dermatol Venereol. 2012; 26 Suppl 1:1-29.

-Zaenglein AL, Pathy AL, Schlosser BJ, Alikhan A, Baldwin HE, Berson DS, Bowe WP, Graber EM, Harper JC, Kang S, Keri JE, Leyden JJ, Reynolds RV, Silverberg NB, Stein Gold LF, Tollefson MM, Weiss JS, Dolan NC, Sagan AA, Stern M, Boyer KM, Bhushan R. Guidelines of care for the management of acne vulgaris. J Am Acad Dermatol. 2016; 74:945-73.

-Rouzès A, Jonville-Béra AP. Isotrétinoïne et grossesse: bilan français de 25 années de suivi. Therapie. 2014; 69:53-63.

-Ebede TL, Arch EL, Berson D. Hormonal treatment of acne in women. J Clin Aesthet Dermatol. 2009; 2(12):16-22.

-Apgar BS, Greenberg G. Using progestins in clinical practice. Am Fam Physician. 2000; 62(8):1839-46, 1849-50.

-Elsaie ML. Hormonal treatment of acne vulgaris: an update. Clin Cosmet Investig Dermatol. 2016; 9:241-8.

-Bosanac SS, Trivedi M, Clark AK, et al. Progestins and acne vulgaris: a review. Dermatol Online J. 2018; 24(5):13030).

-Barbieri JS, Mitra N, Margolis DJ, et al. Influence of contraception class on incidence and severity of acne vulgaris. Obstet Gynecol. 2020; 135(6):1306-12.

-Garg V, Choi JK, James WD, et al. Long-term use of spironolactone for acne in women: a case series of 403 patients. J Am Acad Dermatol. 2021; 84(5):1348-55.

-Thiboutot D, Layton AM, Traore I, Gontijo G, Troielli P, Ju Q, Kurokawa I, Dreno B. International expert consensus recommendations for the use of dermocosmetics in acne. J Eur Acad Dermatol Venereol. 2025; 39(5):952-966.

-van Zuuren EJ, Arents BWM, van der Linden MMD, Vermeulen S, Fedorowicz Z, Tan J. Rosacea: New Concepts in Classification and Treatment. Am J Clin Dermatol. 2021; 22(4):457-465.

-Sharma A, Kroumpouzos G, Kassir M, Galadari H, Goren A, Grabbe S, Goldust M. Rosacea management: A comprehensive review. J Cosmet Dermatol. 2022; 21(5):1895-1904.

-Frazier W, Zemtsov RK, Ge Y. Rosacea: Common Questions and Answers. Am Fam Physician. Am Fam Physician. 2024; 109(6):533-542.

–Anzengruber F, Czernielewski J, Conrad C, Feldmeyer L, Yawalkar N, Häusermann P, Cozzio A, Mainetti C, Goldblum D, Läuchli S, Imhof L, Brand C, Laffitte E, Navarini AA. Swiss S1 guideline for the treatment of rosacea. J Eur Acad Dermatol Venereol. 2017; 31:1775-1791

-Kang CN, Shah M, Tan J. Rosacea: An Update in Diagnosis, Classification and Management. Skin Therapy Lett. 2021; 26(4):1-8.

-Gether L, Overgaard LK, Egeberg A, Thyssen JP. Incidence and prevalence of rosacea: a systematic review and meta-analysis. Br J Dermatol. 2018; 179:282-289.

-Chiriac A, Wollina U. Rosacea in children: a review. Eur J Pediatr. 2023; 182(10):4323-4328.

-Two AM, Wu W, Gallo RL, Hata TR. Rosacea: part I. Introduction, categorization, histology, pathogenesis, and risk factors. J Am Acad Dermatol. 2015; 72:749-58.

-Geng RSQ, Bourkas AN, Mufti A, Sibbald RG. Rosacea: Pathogenesis and Therapeutic Correlates. J Cutan Med Surg. 2024; 28(2):178-189.

-Ahn CS, Huang WW. Rosacea Pathogenesis. Dermatol Clin. 2018; 36(2):81-86.

-Yang F, Wang L, Song D, Zhang L, Wang X, Du D, Jiang X. Signaling pathways and targeted therapy for rosacea. Front Immunol. 2024; 15:1367994.

–Vemuri RC, Gundamaraju R, Sekaran SD, Manikam R. Major pathophysiological correlations of rosacea: a complete clinical appraisal. Int J Med Sci. 2015; 12:387-96.

-Huang YX, Li J, Zhao ZX, Zheng BL, Deng YX, Shi W, Steinhoff M, Xie HF. Effects of skin care habits on the development of rosacea: A multi-center retrospective case-control survey in Chinese population. PLoS One. 2020; 15:e0231078.

-Gallo RL, Granstein RD, Kang S, Mannis M, Steinhoff M, Tan J, Thiboutot D. Standard classification and pathophysiology of rosacea: The 2017 update by the National Rosacea Society Expert Committee. J Am Acad Dermatol. 2018; 78(1):148-155.

-Schiaffino MA, Regula V, Coleman H. Acne, Perioral Dermatitis, Rosacea, and Hidradenitis Suppurativa. Prim Care. 2025; 52(3):593-621.

–Tidman MJ. Improving the management of rosacea in primary care. Practitioner. 2014; 258:27-30.

-Volk K, Ulfers A, Yi RC, Feldman S, Taylor SL. Treatment management for rosacea: current pharmacological and non-pharmacological options. Expert Rev Clin Pharmacol. 2025. doi: 10.1080/17512433.2025.2550727.

-Tüzün Y, Wolf R, Kutlubay Z, Karakuş O, Engin B. Rosacea and rhinophyma. Clin Dermatol. 2014; 32:35-46.

–Searle T, Al-Niaimi F, Ali FR. Rosacea. Br J Hosp Med (Lond). 2021; 82(2):1-8; Kang CN, Shah M, Tan J. Rosacea: An Update in Diagnosis, Classification and Management. Skin Therapy Lett. 2021; 26(4):1-8.

-Clanner-Engelshofen BM, Bernhard D, Dargatz S, Flaig MJ, Gieler U, Kinberger M, Klövekorn W, Kuna AC, Läuchli S, Lehmann P, Nast A, Pleyer U, Schaller M, Schöfer H, Steinhoff M, Schwennesen T, Werner RN, Zierhut M, Reinholz M. S2k guideline: Rosacea. J Dtsch Dermatol Ges. 2022; 20(8):1147-1165.

-Xiao W, Chen M, Wang B, Huang Y, Zhao Z, Deng Z, Xie H, Li J, Tang Y. Efficacy and safety of antibiotic agents in the treatment of rosacea: a systemic network meta-analysis. Front Pharmacol. 2023; 14:1169916.

-Lova Navarro M, Sánchez-Pedreño Guillen P, Victoria Martínez AM, Martínez Menchón T, Corbalán Vélez R, Frías Iniesta J. Papulopustular Rosacea: Response to Treatment with Oral Azithromycin. Actas Dermosifiliogr (Engl Ed). 2018; 109(6):529-535.

-Nagler AR, Del Rosso J. The Use of Oral Antibiotics in the Management of Rosacea. J Drugs Dermatol. 2019; 18:506.

–Logger JGM, Olydam JI, Driessen RJB. Use of beta-blockers for rosacea-associated facial erythema and flushing: a systematic review and update on proposed mode of action. J Am Acad Dermatol. 2020. pii: S0190-9622(20)30750-7.

-Wang YA, James WD. Update on rosacea classification and its controversies. Cutis. 2019; 104:70-73.

-van Zuuren EJ, Fedorowicz Z, Tan J, van der Linden MMD, Arents BWM, Carter B, Charland L. Interventions for rosacea based on the phenotype approach: an updated systematic review including GRADE assessments. Br J Dermatol. 2019; 181(1):65-79.

-Titus S, Hodge J. Diagnosis and treatment of acne. Am Fam Physician. 2012; 86:734-40.

–Schmutz JL. Signes cliniques de la rosacée. Ann Dermatol Venereol. 2014; 141 Suppl 2:S151-7.

-Haber R, El Gemayel M. Comorbidities in rosacea: A systematic review and update. J Am Acad Dermatol. 2018; 78:786-792.

-Chen Q, Shi X, Tang Y, Wang B, Xie HF, Shi W, Li J. Association between Rosacea and Cardiometabolic Disease: A Systematic Review and Meta-Analysis. J Am Acad Dermatol. 2020. pii: S0190-9622(20)30729-5.

-Two AM, Wu W, Gallo RL, Hata TR. Rosacea: part II. Topical and systemic therapies in the treatment of rosacea. J Am Acad Dermatol. 2015; 72:761-70

-Micheletti RG. An update on the diagnosis and treatment of hidradenitis suppurativa. Cutis. 2015; 96(6 Suppl):7-12.

-Zouboulis CC, Desai N, Emtestam L, Hunger RE, Ioannides D, Juhász I, Lapins J, Matusiak L, Prens EP, Revuz J, Schneider-Burrus S, Szepietowski JC, van der Zee HH, Jemec GB. European S1 guideline for the treatment of hidradenitis suppurativa/acne inversa. J Eur Acad Dermatol Venereol. 2015; 29:619-44.

-Anzengruber F, Czernielewski J, Conrad C, Feldmeyer L, Yawalkar N, Häusermann P, Cozzio A, Mainetti C, Goldblum D, Läuchli S, Imhof L, Brand C, Laffitte E, Navarini AA. Swiss S1 guideline for the treatment of rosacea. J Eur Acad Dermatol Venereol. 2017; 31:1775-1791

-Ebbelaar CCF, Venema AW, Van Dijk MR. Topical Ivermectin in the Treatment of Papulopustular Rosacea: A Systematic Review of Evidence and Clinical Guideline Recommendations. Dermatol Ther (Heidelb). 2018; 8:379-387.

-Sobolewska B, Doycheva D, Deuter CM, Schaller M, Zierhut M. Efficacy of Topical Ivermectin for the Treatment of Cutaneous and Ocular Rosacea. Ocul Immunol Inflamm. 2020 Apr 7:1-5.

-Lipozenčić J, Hadžavdić SL. Perioral dermatitis.Clin Dermatol. 2014; 32:125-30.

-Brunetti T, Chessa MA, Leuzzi M, Gurioli C, Cedirian S, Neri I. Pediatric Perioral Dermatitis Associated with Inhaled Corticosteroids: A Retrospective Case Series. Dermatol Pract Concept. 2025; 15(2):5239.

-Tolaymat L, Syed HA, Hall MR. Perioral Dermatitis. 2025 Jul 6. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan–.

-Searle T, Ali FR, Al-Niaimi F. Perioral dermatitis: Diagnosis, proposed etiologies, and management. J Cosmet Dermatol. 2021; 20(12):3839-3848.

-Tempark T, Shwayder TA. Perioral dermatitis: a review of the condition with special attention to treatment options. Am J Clin Dermatol. 2014; 15:101-13.

-Mochizuki A, Osaka T, Fukuya Y, Yanagisawa N, Ishiguro N. Comparative Analysis of the Skin Microbiota of Rosacea, Steroid-Induced Rosacea and Perioral Dermatitis. Exp Dermatol. 2025; 34(3):e70084.

-Milagre ACX, Almeida APM, Rezende HD, Almeida LM, Peçanha MAP. Granulomatous perioral dermatitis with extra-facial involvement in childhood: good therapeutic response with oral azithromycin. Rev Paul Pediatr. 2018; 36:511-514.

-Lee SH, Kim HS. Childhood Granulomatous Periorificial Dermatitis. J Cutan Med Surg. 2022; 26(6):655.

-Shropshire C, Shawa H, Shreve C, Cotter D. Perioral Allergic Contact Dermatitis in Association With Vaping. Dermatitis. 2021; 32(6):e144-e145.

-Wang Q, Zhan AT, Qiu F, Fan YM. Perioral contact dermatitis due to Chinese waterpipe smoking in two men. Contact Dermatitis. 2022; 86(3):219-221.

-Jagannathan K, Vijayanand S, Manoharan D, Indiran V. Perioral Rash in a Young Boy Due to Lip-Licking Dermatitis. Indian J Pediatr. 2022; 89(5):513-514.

-Ahmed G, Pal S, Esquinas AM, Karim HMR. Perioral Dermatitis Caused by Improper Use of Activated Oxygen in CPAP users and its Complexity. J Clin Aesthet Dermatol. 2022; 15(8):14.

-Nahm WJ, Nagler AR, Milam EC. Association of perioral dermatitis with facial mask usage during the COVID-19 pandemic: A retrospective study. JAAD Int. 2023; 10:86-87.

-Lee GL, Zirwas MJ. Granulomatous Rosacea and Periorificial Dermatitis: Controversies and Review of Management and Treatment. Dermatol Clin. 2015; 33:447-55.

causes, clinical presentation, and management strategies for these entities.

–Hall CS, Reichenberg J. Evidence based review of perioral dermatitis therapy. G Ital Dermatol Venereol. 2010; 145:433-44.

–Ollech A, Yousif R, Kruse L, Wagner A, Kenner-Bell B, Chamlin S, Yun D, Shen L, Vivar K, Reynolds M, Paller AS, Mancini AJ. Topical calcineurin inhibitors for pediatric periorificial dermatitis. J Am Acad Dermatol. 2020. pii: S0190-9622(20)30150-X.

-Kellen R, Silverberg NB. Pediatric periorificial dermatitis. Cutis. 2017; 100:385-388).

-Goldburg SR, Strober BE, Payette MJ. Hidradenitis suppurativa: Epidemiology, clinical presentation, and pathogenesis. J Am Acad Dermatol. 2020; 82(5):1045-1058.

-van Straalen KR, Ma F, Tsou PS, Plazyo O, Gharaee-Kermani M, Calbet M, Xing X, Sarkar MK, Uppala R, Harms PW, Wasikowski R, Nahlawi L, Nakamura M, Eshaq M, Wang C, Dobry C, Kozlow JH, Cherry-Bukowiec J, Brodie WD, Wolk K, Uluçkan Ö, Mattichak MN, Pellegrini M, Modlin RL, Maverakis E, Sabat R, Kahlenberg JM, Billi AC, Tsoi LC, Gudjonsson JE. Single-cell sequencing reveals Hippo signaling as a driver of fibrosis in hidradenitis suppurativa. J Clin Invest. 2024; 134(3):e169225.

-Zouboulis CC, Bechara FG, Benhadou F, Bettoli V, Bukvić Mokos Z, Del Marmol V, Dolenc-Voljč M, Giamarellos-Bourboulis EJ, Grimstad Ø, Guillem P, Horváth B, Hunger RE, Ingram JR, Ioannidis D, Just E, Kemény L, Kirby B, Liakou AI, McGrath BM, Marzano AV, Matusiak Ł, Molina-Leyva A, Nassif A, Podda M, Prens EP, Prignano F, Raynal H, Romanelli M, Saunte DML, Szegedi A, Szepietowski JC, Tzellos T, Valiukevičienė S, van der Zee HH, van Straalen KR, Villumsen B, Jemec GBE. European S2k guidelines for hidradenitis suppurativa/acne inversa part 2: Treatment. J Eur Acad Dermatol Venereol. 2025; 39(5):899-941.

-Garg A, Neuren E, Cha D, Kirby JS, Ingram JR, Jemec GBE, Esmann S, Thorlacius L, Villumsen B, Marmol VD, Nassif A, Delage M, Tzellos T, Moseng D, Grimstad Ø, Naik H, Micheletti R, Guilbault S, Miller AP, Hamzavi I, van der Zee H, Prens E, Kappe N, Ardon C, Kirby B, Hughes R, Zouboulis CC, Nikolakis G, Bechara FG, Matusiak L, Szepietowski J, Glowaczewska A, Smith SD, Goldfarb N, Daveluy S, Avgoustou C, Giamarellos-Bourboulis E, Cohen S, Soliman Y, Brant EG, Akilov O, Sayed C, Tan J, Alavi A, Lowes MA, Pascual JC, Riad H, Fisher S, Cohen A, Paek SY, Resnik B, Ju Q, Wang L, Strunk A. Evaluating patients’ unmet needs in hidradenitis suppurativa: results from the Global Survey of Impact and Healthcare Needs (VOICE) Project. J Am Acad Dermatol 2020; 82: 366-76.

-Kokolakis G, Wolk K, Schneider-Burrus S, Kalus S, Barbus S, Gomis-Kleindienst S, Sabat R. Delayed diagnosis of hidradenitis suppurativa and its effect on patients and healthcare system. Dermatology 2020; 236: 421–30.

-Saunte DML, Jemec GBE. Hidradenitis Suppurativa: Advances in Diagnosis and Treatment. JAMA. 2017; 318(20):2019-2032.

-Phan K, Charlton O, Smith SD. Hidradenitis suppurativa and metabolic syndrome – systematic review and adjusted meta-analysis. Int J Dermatol. 2019; 58(10):1112-1117.

-Mintoff D, Benhadou F, Pace NP, Frew JW. Metabolic syndrome and hidradenitis suppurativa: epidemiological, molecular, and therapeutic aspects. Int J Dermatol. 2022; 61(10):1175-1186.

-Garg A, Malviya N, Strunk A, Wright S, Alavi A, Alhusayen R, Alikhan A, Daveluy SD, Delorme I, Goldfarb N, Gulliver W, Hamzavi I, Jaleel T, Kimball AB, Kirby JS, Kirchhof MG, Lester J, Lev-Tov H, Lowes MA, Micheletti R, Orenstein LA, Piguet V, Sayed C, Tan J, Naik HB. Comorbidity screening in hidradenitis suppurativa: Evidence-based recommendations from the US and Canadian Hidradenitis Suppurativa Foundations. J Am Acad Dermatol. 2022; 86(5):1092-1101.

-Zhang M, Chen QD, Xu HX, Xu YM, Chen HJ, Yang BL. Association of hidradenitis suppurativa with Crohn’s disease. World J Clin Cases. 2021; 9(15):3506-3516.

-Krajewski PK, Strobel A, Schultheis M, Staubach P, Grabbe S, Hennig K, Matusiak L, von Stebut E, Garcovich S, Bayer H, Heise M, Kirschner U, Nikolakis G, Szepietowski JC. Profound Sexual Dysfunction Among Patients with Hidradenitis Suppurativa: A Cross-sectional Study. Dermatol Ther (Heidelb). 2024; 14(7):1823-1838.

-Caliezi A, Rabufetti A, Hunger R, Wolf R, Seyed Jafari SM. Impact of Hidradenitis Suppurativa on Sexual Quality of Life. J Clin Med. 2025; 14(3):910.

-Wolkenstein P, Loundou A, Barrau K, Auquier P, Revuz J. Quality of life impairment in Hidradenitis suppurativa: a study of 61 cases. J Am Acad Dermatol 2007; 56:621-3.

-Schneider-Burrus S, Lux G, van der Linde K, Barbus S, Huss-Marp J, Tsaousi A, Wasem J, Wolff B, Sabat R. Hidradenitis suppurativa – prevalence analyses of German statutory health insurance data. J Eur Acad Dermatol Venereol 2021; 35: e32–35.

-Jenkins T, Isaac J, Edwards A, Okoye GA. Hidradenitis Suppurativa. Dermatol Clin. 2023; 41(3):471-479.

-Cotton CH, Chen SX, Hussain SH, Lara-Corrales I, Zaenglein AL. Hidradenitis Suppurativa in Pediatric Patients. Pediatrics. 2023; 151(5):e2022061049.

-van der Weijden DAY, Koerts NDK, van Munster BC, van der Zee HH, Horváth B. Hidradenitis suppurativa tarda: defining an understudied elderly population. Br J Dermatol 2023; 190:105-13.

-Sabat R, Tsaousi A, Ghoreschi K, Wolk K, Schneider-Burrus S. Sex disaggregated population analysis in patients with hidradenitis suppurativa. Front Med 2022; 9:1028943.

-Hessam S, Bechara FG. Hidradenitis suppurativa/Acne inversa in der Genitoanalregion. Hautarzt. 2020; 71:256-26.

-Margesson LJ, Danby FW. Hidradenitis suppurativa. Best Pract Res Clin Obstet Gynaecol. 2014; 28:1013-27.

-Zouboulis CC, Tzellos T, Kyrgidis A, Jemec GBE, Bechara FG, Giamarellos-Bourboulis EJ, Ingram JR, Kanni T, Karagiannidis I, Martorell A, Matusiak Ł, Pinter A, Prens EP, Presser D, Schneider-Burrus S, von Stebut E, Szepietowski JC, van der Zee HH, Wilden SM, Sabat R; European Hidradenitis Suppurativa Foundation Investigator Group. Development and validation of the International Hidradenitis Suppurativa Severity Score System (IHS4), a novel dynamic scoring system to assess HS severity. Br J Dermatol 2017; 177: 1401-09.

-Kirby JS, Thorlacius L, Villumsen B, Ingram JR, Garg A, Christensen KB, Butt M, Esmann S, Tan J, Jemec GBE. The Hidradenitis Suppurativa Quality of Life (HiSQOL) score: development and validation of a measure for clinical trials. Br J Dermatol 2020; 183: 340-48.

-Zouboulis CC, Prens EP, Sayed CJ, Molina-Leyva A, Bettoli V, Romanelli M, Szepietowski JC, Martinez AL, Kasparek T, Lobach I, Wozniak MB, Ortmann CE, Thomas N, Bachhuber T, Ravichandran S, Tzellos T. International hidradenitis Suppurativa severity scoring system (IHS4) as a holistic measure of hidradenitis suppurativa disease severity compared with Hurley staging: a post hoc analysis of the SUNRISE and SUNSHINE phase 3 trials of secukinumab. J Eur Acad Dermatol Venereol. 2024; 38(6):e496–e499.

-Danby FW, Jemec GB, Marsch WCh, von Laffert M. Preliminary findings suggest hidradenitis suppurativa may be due to defective follicular support. Br J Dermatol. 2013; 168:1034-9.

-Hessam S, Sand M, Gambichler T, Skrygan M, Rüddel I, Bechara FG. Interleukin-36 in hidradenitis suppurativa: evidence for a distinctive proinflammatory role and a key factor in the development of an inflammatory loop. Br J Dermatol. 2018; 178:761-767.

-Grand D, Navrazhina K, Frew JW. Integrating complement into the molecular pathogenesis of Hidradenitis Suppurativa. Exp Dermatol. 2020; 29:86-92.

-Zouboulis CC, Desai N, Emtestam L, Hunger RE, Ioannides D, Juhász I, Lapins J, Matusiak L, Prens EP, Revuz J, Schneider-Burrus S, Szepietowski JC, van der Zee HH, Jemec GB. European S1 guideline for the treatment of hidradenitis suppurativa/acne inversa. J Eur Acad Dermatol Venereol. 2015; 29:619-44.

-Hessam S, Scholl L, Sand M, Schmitz L, Reitenbach S, Bechara FG. A Novel Severity Assessment Scoring System for Hidradenitis Suppurativa. JAMA Dermatol. 2018; 154:330-335.

-Danby FW. Diet in the prevention of hidradenitis suppurativa (acne inversa). J Am Acad Dermatol. 2015; 73(5 Suppl 1):S52-4.

-Vellaichamy G, Braunberger TL, Nahhas AF, Hamzavi IH. Surgical procedures for hidradenitis suppurativa. Cutis. 2018; 102:13-16.

-Shipman WD 3rd, Williams MN, Suozzi KC, Eisenstein AS, Dover JS. Efficacy of laser hair removal in hidradenitis suppurativa: A systematic review and meta-analysis. Lasers Surg Med. 2024; 56(5):425-436.

-Zouboulis CC, Bechara FG, Dickinson-Blok JL, Gulliver W, Horváth B, Hughes R, Kimball AB, Kirby B, Martorell A, Podda M, Prens EP, Ring HC, Tzellos T, van der Zee HH, van Straalen KR, Vossen ARJV, Jemec GBE. Hidradenitis suppurativa/acne inversa: A practical framework for treatment optimization -systematic review and recommendations from the HS ALLIANCE working group. J Eur Acad Dermatol Venereol. 2019; 33:19-31.

-Goldburg SR, Strober BE, Payette MJ. Hidradenitis suppurativa: Epidemiology, clinical presentation, and pathogenesis. J Am Acad Dermatol. 2020; 82(5):1045-1058.

-Yu CC, Cook MG. Hidradenitis suppurativa: a disease of follicular epithelium, rather than apocrine glands. Br J Dermatol 1990; 122: 763–69.

-Sabat R, Jemec GBE, Matusiak Ł, Kimball AB, Prens E, Wolk K. Hidradenitis suppurativa. Nat Rev Dis Primers 2020; 6:18.

-Świerczewska Z, Lewandowski M, Surowiecka A, Barańska-Rybak W. Microbiome in Hidradenitis Suppurativa-What We Know and Where We Are Heading. Int J Mol Sci. 2022; 23(19):11280.

-van Straalen KR, Prens EP, Gudjonsson JE. Insights into hidradenitis suppurativa. J Allergy Clin Immunol. 2022; 149(4):1150–1161.

–Gudjonsson JE, Tsoi LC, Ma F, Billi AC, van Straalen KR, Vossen ARJV, van der Zee HH, Harms PW, Wasikowski R, Yee CM, Rizvi SM, Xing X, Xing E, Plazyo O, Zeng C, Patrick MT, Lowe MM, Burney RE, Kozlow JH, Cherry-Bukowiec JR, Jiang Y, Kirma J, Weidinger S, Cushing KC, Rosenblum MD, Berthier C, MacLeod AS, Voorhees JJ, Wen F, Kahlenberg JM, Maverakis E, Modlin RL, Prens EP. Contribution of plasma cells and B cells to hidradenitis suppurativa pathogenesis. JCI Insight. 2020; 5(19):e139930.

-van der Zee HH, de Ruiter L, Boer J, van den Broecke DG, den Hollander JC, Laman JD, Prens EP. Alterations in leucocyte subsets and histomorphology in normal-appearing perilesional skin and early and chronic hidradenitis suppurativa lesions. Br J Dermatol 2012; 166: 98-106.

-Dunstan RW, Salte KM, Todorović V, Lowe M, Wetter JB, Harms PW, Burney RE, Scott VE, Smith KM, Rosenblum MD, Gudjonsson JE, Honore P. Histologic progression of acne inversa/hidradenitis suppurativa: implications for future investigations and therapeutic intervention. Exp Dermatol 2021; 30: 820-30.

-van Straalen KR, Ma F, Tsou PS, Plazyo O, Gharaee-Kermani M, Calbet M, Xing X, Sarkar MK, Uppala R, Harms PW, Wasikowski R, Nahlawi L, Nakamura M, Eshaq M, Wang C, Dobry C, Kozlow JH, Cherry-Bukowiec J, Brodie WD, Wolk K, Uluçkan Ö, Mattichak MN, Pellegrini M, Modlin RL, Maverakis E, Sabat R, Kahlenberg JM, Billi AC, Tsoi LC, Gudjonsson JE. Single-cell sequencing reveals Hippo signaling as a driver of fibrosis in hidradenitis suppurativa. J Clin Invest. 2024; 134(3):e169225.

-Canoui-Poitrine F, Revuz JE, Wolkenstein P, Viallette C, Gabison G, Pouget F, Poli F, Faye O, Bastuji-Garin S. Clinical characteristics of a series of 302 French patients with hidradenitis suppurativa, with an analysis of factors associated with disease severity. J Am Acad Dermatol 2009; 61: 51-57.

-van Straalen KR, Prens EP, Willemsen G, Boomsma DI, van der Zee HH. Contribution of genetics to the susceptibility to hidradenitis suppurativa in a large, cross-sectional Dutch twin cohort. JAMA Dermatol 2020; 156: 1359-62.

-Kjaersgaard Andersen R, Clemmensen SB, Larsen LA, Hjelmborg JVB, Ødum N, Jemec GBE, Christensen K. Evidence of gene-gene interaction in hidradenitis suppurativa: a nationwide registry study of Danish twins. Br J Dermatol 2022; 186: 78-85.

-Vellaichamy G, Amin AT, Dimitrion P, Hamzavi Z, Zhou L, Adrianto I, Mi QS. Recent advances in hidradenitis suppurativa: Role of race, genetics, and immunology. Front Genet. 2022; 13:918858.

-Wolk K, Join-Lambert O, Sabat R. Aetiology and pathogenesis of hidradenitis suppurativa. Br J Dermatol 2020; 183: 999-1010; Sabat R, Alavi A, Wolk K, Wortsman X, McGrath B, Garg A, Szepietowski JC. Hidradenitis suppurativa. Lancet. 2025; 405(10476):420-438.

-Sabat R, Šimaitė D, Gudjonsson JE, Brembach TC, Witte K, Krause T, Kokolakis G, Bartnik E, Nikolaou C, Rill N, Coulibaly B, Levin C, Herrmann M, Salinas G, Leeuw T, Volk HD, Ghoreschi K, Wolk K. Neutrophilic granulocyte derived B-cell activating factor supports B cells in skin lesions in hidradenitis suppurativa. J Allergy Clin Immunol 2023; 151: 1015-26.

-Sun Q, Broadaway KA, Edmiston SN, Fajgenbaum K, Miller-Fleming T, Westerkam LL, Melendez-Gonzalez M, Bui H, Blum FR, Levitt B, Lin L, Hao H, Harris KM, Liu Z, Thomas NE, Cox NJ, Li Y, Mohlke KL, Sayed CJ. Genetic Variants Associated With Hidradenitis Suppurativa. JAMA Dermatol. 2023; 159(9):930-938.

-Kathju S, Lasko LA, Stoodley P. Considering hidradenitis suppurativa as a bacterial biofilm disease. FEMS Immunol Med Microbiol 2012; 65:385-389.

-Jahns AC, Killasli H, Nosek D, Lundskog B, Lenngren A, Muratova Z, Emtestam L, Alexeyev OA. Microbiology of hidradenitis suppurativa (acne inversa): a histological study of 27 patients. APMIS 2014; 122:804-809.

-Nikolakis G, Liakou AI, Bonovas S, Seltmann H, Bonitsis N, Join-Lambert O, Wild T, Karagiannidis I, Zolke-Fischer S, Langner K, Zouboulis CC. Bacterial Colonization in Hidradenitis Suppurativa/Acne Inversa: A Cross-sectional Study of 50 Patients and Review of the Literature. Acta Derm Venereol. 2017; 97(4):493-498.

-Fimmel S, Zouboulis CC. Comorbidities of hidradenitis suppurativa (acne inversa). Dermatoendocrinol 2010; 2:9-16.

-Nikolakis G, Liakou AI, Bonovas S, Seltmann H, Bonitsis N, Join-Lambert O, Wild T, Karagiannidis I, Zolke-Fischer S, Langner K, Zouboulis CC. Bacterial Colonization in Hidradenitis Suppurativa/Acne Inversa: A Cross-sectional Study of 50 Patients and Review of the Literature. Acta Derm Venereol. 2017; 97(4):493-498.

-Williams SC, Garcet S, Hur H, Miura S, Gonzalez J, Navrazhina K, Yamamura-Murai M, Yamamura K, Li X, Frew J, Fischetti VA, Sela U, Krueger JG. Gram-negative anaerobes elicit a robust keratinocytes immune response with potential insights into HS pathogenesis. Exp Dermatol. 2024; 33(5):e15087.

-Soto-Moreno A, Haselgruber-de Francisco S, León-Pérez J, García-Moronta C, Cuenca Barrales C, Arias-Santiago S, Molina Leyva A. The Microbiome in Hidradenitis Suppurativa Tunnels: A Systematic Review. Int J Dermatol. 2025. doi: 10.1111.

-Williams SC, Garcet S, Hur H, Miura S, Gonzalez J, Navrazhina K, Yamamura-Murai M, Yamamura K, Li X, Frew J, Fischetti VA, Sela U, Krueger JG. Gram-negative anaerobes elicit a robust keratinocytes immune response with potential insights into HS pathogenesis. Exp Dermatol. 2024; 33(5):e15087.

-Kirby JS, Thorlacius L, Villumsen B, Ingram JR, Garg A, Christensen KB, Butt M, Esmann S, Tan J, Jemec GBE. The Hidradenitis Suppurativa Quality of Life (HiSQOL) score: development and validation of a measure for clinical trials. Br J Dermatol. 2020 ;183(2):340-348.

-Hickerson N, Gruzmark F, Danker S, Lev-Tov H. Addressing the Dressings: Wound Care in Hidradenitis Suppurativa. Dermatol Clin. 2025; 43(2):261-272.

-Nikolakis G, Kyrgidis A, Zouboulis CC. Is There a Role for Antiandrogen Therapy for Hidradenitis Suppurativa? A Systematic Review of Published Data. Am J Clin Dermatol. 2019; 20(4):503-513.

-Saunte DML, Jemec GBE. Hidradenitis Suppurativa: Advances in Diagnosis and Treatment. JAMA. 2017; 318(20):2019-2032.

-Sabat R, Alavi A, Wolk K, Wortsman X, McGrath B, Garg A, Szepietowski JC. Hidradenitis supurativa. Lancet. 2025; 405(10476):420-438.

-Nikolakis G, von Stebut E. Lokale und neue apparative Therapien der milden Hidradenitis suppurativa. Hautarzt. 2021; 72(8):676-685.

-Molinelli E, Brisigotti V, Simonetti O, Sapigni C, D’Agostino GM, Rizzetto G, Giacchetti A, Offidani A. Efficacy and safety of topical resorcinol 15% versus topical clindamycin 1% in the management of mild-to-moderate hidradenitis suppurativa: A retrospective study. Dermatol Ther. 2022; 35(6):e15439.

-Hundal S, Cappelli J, Croitoru D, Drucker AM, Ingram JR, Goldberg SR, Netchiporouk E. Cost-utility analysis of clinic-based deroofing versus local excision for hidradenitis suppurativa. J Am Acad Dermatol. 2025; 92(4):773-780.

-Clark SR, Soti V. Effectiveness of Surgical Deroofing and Carbon Dioxide Laser in Moderate-to-Severe Hidradenitis Suppurativa Patients. Cureus. 2024; 16(3):e56959.

-Masson R, Park S, Shi VY, Hsiao JL, Aleshin MA. Expert Practices in Hidradenitis Suppurativa Flare Management: A Cross-Sectional Survey Study. Skin Appendage Disord. 2024; 10(3):224-228..

-Cuenca- Barrales C, Montero- Vílchez T, Sánchez- Díaz M, Martínez- López A, Rodríguez-Pozo JÁ, Díaz- Calvillo P, Arias-Santiago S, Molina-Leyva A. Intralesional treatments in hidradenitis Suppurativa: a systematic review. Dermatol Basel Switz. 2022; 238(6):1084-91.

-Sánchez AR, Rogers RS, Sheridan PJ. Tetracycline and other tetracycline- derivative staining of the teeth and oral cavity. Int J Dermatol. 2004; 43(10):709–15.

-van Straalen KR, Tzellos T, Alavi A, Benhadou F, Cuenca- Barrales C, Daxhelet M, Daoud M, Efthymiou O, Giamarellos-Bourboulis EJ, Guillem P, Gulliver W, Jemec GBE, Katoulis A, Koenig A, Lazaridou E, Lowes MA, Marzano AV, Matusiak L, Molina-Leyva A, Moltrasio C, Pinter A, Potenza C, Prens EP, Romaní J, Saunte DM, Sayed C, Skroza N, Stergianou D, Szepietowski JC, Trigoni A, Vilarrasa E, Kyrgidis A, Zouboulis CC, van der Zee HH. External validation of the IHS4- 55 in a European antibiotic- treated hidradenitis Suppurativa cohort. Dermatol Basel Switz. 2023; 239(3):362-7.

-Delage M, Jais JP, Lam T, Guet-Revillet H, Ungeheuer MN, Consigny PH, Nassif A, Join-Lambert O. Rifampin-moxifloxacin-metronidazole combination therapy for severe Hurley stage 1 hidradenitis suppurativa: prospective short-term trial and 1-year follow-up in 28 consecutive patients. J Am Acad Dermatol. 2023; 88(1):94-100.

-Zouboulis CC, Desai N, Emtestam L, Hunger RE, Ioannides D, Juhász I, et al. European S1 guideline for the treatment of hidradenitis suppurativa/acne inversa. J Eur Acad Dermatol Venereol. 2015;29(4):619-44.

-Ingram JR, Collier F, Brown D, Burton T, Burton J, Chin MF, et al. British Association of Dermatologists guidelines for the management of hidradenitis suppurativa (acne inversa) 2018. Br J Dermatol. 2019; 180(5):1009-17.

-Fischer AH, Haskin A, Okoye GA. Patterns of antimicrobial resistance in lesions of hidradenitis suppurativa. J Am Acad Dermatol. 2017; 76(2):309-313.

-Leiphart P, Ma H, Naik HB, Kirby JS. The effect of antimicrobial washes on antibacterial resistance in hidradenitis suppurativa lesions. J Am Acad Dermatol. 2019; 80(3):821-2.

-European Centre for Disease Prevention and Control and World Health Organization, 2023.

-Koumaki D, Evangelou G, Maraki S, Rovithi E, Petrou D, Apokidou ES, Gregoriou S, Koumaki V, Ioannou P, Zografaki K, Doxastaki A, Katoulis A, Papadopoulou K, Stafylaki D, Mavromanolaki VE, Krasagakis K. Antimicrobial Resistance Trends in Hidradenitis Suppurativa Lesions. J Clin Med. 2024 Jul 20;13(14):4246.

-Kimball AB, Okun MM, Williams DA, Gottlieb AB, Papp KA, Zouboulis CC, Armstrong AW, Kerdel F, Gold MH, Forman SB, Korman NJ, Giamarellos-Bourboulis EJ, Crowley JJ, Lynde C, Reguiai Z, Prens EP, Alwawi E, Mostafa NM, Pinsky B, Sundaram M, Gu Y, Carlson DM, Jemec GB. Two phase 3 trials of Adalimumab for hidrade nitis Suppurativa. N Engl J Med. 2016; 375(5):422–34.

-Lee RA, Eisen DB. Treatment of hidradenitis suppurativa with biologic medications. J Am Acad Dermatol. 2015; 73(5 Suppl 1):S82-8.

–Puig L, López-Ferrer A. Biosimilars for the treatment of psoriasis. Expert Opin Biol Ther. 2019; 19:993-1000.

-Erbağcı E, Bakay ÖSK, Hapa FA. Secukinumab Treatment in Patients with Hidradenitis Suppurativa in Real-World Clinical Settings: A Multicenter Study. Dermatol Pract Concept. 2025; 15(1):4915.

-Calabrese L, Cartocci A, Rubegni P, French LE, Kendziora B. Efficacy and safety of biologics for hidradenitis suppurativa: A network meta-analysis of phase III trials. J Eur Acad Dermatol Venereol. 2025. doi: 10.1111/jdv.20617.

-Rabindranathnambi A, Jeevankumar B. Dapsone in Hidradenitis Suppurativa: A Systematic Review. Dermatol Ther (Heidelb). 2022; 12(2):285-293.

–Tan MG, Shear NH, Walsh S, Alhusayen R. Acitretin. J Cutan Med Surg. 2017; 21(1):48-53.

-Boer J, Nazary M. Long- term results of acitretin therapy for hidrad enitis suppurativa. Is acne inversa also a misnomer? Br J Dermatol. 2011; 164(1):170-5.

-Matusiak L, Bieniek A, Szepietowski JC. Acitretin treatment for hidradenitis suppurativa: a prospective series of 17 patients. Br J Dermatol. 2014; 171(1):170-4.

-Bouwman K, Aarts P, Dudink K, Hao J, Alizadeh BZ, Prens LM, Vossen ARJV, van Straalen KR, van der Zee HH, Horváth B. Drug Survival of Oral Retinoids in Hidradenitis Suppurativa: A Real-Life Cohort Study. Am J Clin Dermatol. 2022; 23(6):905-914.

-Alhusayen R, Shear NH. Scientific evidence for the use of current traditional systemic therapies in patients with hidradenitis suppurativa. J Am Acad Dermatol. 2015; 73(5 Suppl 1):S42–S46.

-Wong D, Walsh S, Alhusayen R. Low-dose systemic corticosteroid treatment for recalcitrant hidradenitis suppurativa. J Am Acad Dermatol. 2016; 75(5):1059-62.

-Saylor DK, Brownstone ND, Naik HB. Office- based surgical intervention for Hidradenitis Suppurativa (HS): a focused review for dermatologists. Dermatol Ther. 2020;10(4):529-49.

-van Hattem S, Spoo JR, Horváth B, Jonkman MF, Leeman FWJ. Surgical treatment of sinuses by deroofing in hidradenitis suppurativa. Dermatol Surg. 2012; 38(3):494-7.

-Hendricks AJ, Hsiao JL, Lowes MA, Shi VY. A Comparison of International Management Guidelines for Hidradenitis Suppurativa. Dermatology. 2019 23:1-16.

-Scholl L, Hessam S, Reitenbach S, Bechara FG. Operative Behandlungsoptionen bei Hidradenitis suppurativa/Acne inversa. Hautarzt. 2018; 69:149-16.

-Riddle A, Westerkam L, Feltner C, Sayed C. Current surgical Management of Hidradenitis Suppurativa: a systematic review and meta- analysis. Dermatol Surg. 2021; 47(3):349-54.

-Ovadja ZN, Zugaj M, Jacobs W, van der Horst CMAM, Lapid O. Recurrence rates following reconstruction strategies after wide excision of hidradenitis Suppurativa: a systematic review and meta-analysis. Dermatol Surg. 2021; 47(4):e106-e110.

-Moazenzadeh M, Bashash M, Bechara FG, Zwingerman N, Moazenzadeh M, Bashash M, Sibbald RG, Alavi A. Recurrence of hidradenitis suppurativa after surgical management: a systematic review and meta- analysis. J Am Acad Dermatol. 2015; 73(5 Suppl 1):S70-S77.

-van Rappard DC, Mooij JE, Mekkes JR. Mild to moderate hidradenitis suppurativa treated with local excision and primary closure. J Eur Acad Dermatol Venereol. 2012; 26(7):898-902.

-Afsharfard A, Khodaparast MB, Zarrintan S, Yavari N. Comparison of Split thickness skin grafts and flaps in bilateral chronic axillary hidradenitis Suppurativa. World J Plast Surg. 2020; 9(1):55-6.

-van der Zee HH, Prens EP, Boer J. Deroofing: a tissue-saving surgical technique for the treatment of mild to moderate Hidradenitis suppurativa lesions. J Am Acad Dermatol 2010; 63:475-80.

-Aranda Sánchez N, Sánchez Moya AI, Molina Figuera E, Gargallo Quintero AB. Impact of Seton Placement on Fistula Treatment in Hidradenitis Suppurativa: A Before-and-After Analysis. Actas Dermosifiliogr. 2025; 116(7):T802-T804.

-Hazen PG, Hazen BP. Hidradenitis suppurativa: successful treatment using carbon dioxide laser excision and marsupialization. Dermatol Surg. 2010; 36(2):208-13.

-Finley EM, Ratz JL. Treatment of hidradenitis suppurativa with carbon dioxide laser excision and second-intention healing. J Am Acad Dermatol. 1996; 34(3):465-9.

-Sherman AI, Reid R. CO₂ laser for suppurative hidradenitis of the vulva. J Reprod Med. 1991; 36(2):113-7.

-Lapins J, Marcusson JA, Emtestam L. Surgical treatment of chronic hidradenitis suppurativa: CO₂ laser stripping-secondary intention technique. Br J Dermatol. 1994; 131(4):551-6.

-Sechi A, Caposiena Caro RD, Michelucci A, Dini V, Piaserico S, Zalaudek I, Savoia F, Tartaglia J. CO₂ Laser Versus Surgical Deroofing for the Treatment of Hidradenitis Suppurativa Tunnels: A Comparative Multicentric, Retrospective Study. Dermatol Surg. 2025; 51(4):389-395.

-Join-Lambert O, Coignard-Biehler H, Jais JP, Delage M, Guet- Revillet H, Poirée S, Duchatelet S, Jullien V, Hovnanian A, Lortholary O, Nassif X, Nassif A. Efficacy of ertapenem in severe hidradenitis suppurativa: a pilot study in a cohort of 30 consecutive patients. J Antimicrob Chemother. 2016; 71(2):513-20.

-Nosrati A, Ch’en PY, Torpey ME, Shokrian N, Ball G, Benesh G, Andriano TM, Zhu TR, Heibel HD, Hosgood HD, Campton KL, Cohen SR. Efficacy and Durability of Intravenous Ertapenem Therapy for Recalcitrant Hidradenitis Suppurativa. JAMA Dermatol. 2024; 160(3):312-318.

-DeFazio MV, Economides JM, King KS, Han KD, Shanmugam VK, Attinger CE, Evans KK. Outcomes after combined radical resection and targeted biologic therapy for the Management of Recalcitrant Hidradenitis Suppurativa. Ann Plast Surg. 2016; 77(2):217-22.

-Join-Lambert O, Coignard-Biehler H, Jais JP, Delage M, Guet- Revillet H, , Poirée S, Duchatelet S, Jullien V, Hovnanian A, Lortholary O, Nassif X, Nassif A. Efficacy of ertapenem in severe hidradeni tis suppurativa: a pilot study in a cohort of 30 consecutive patients. J Antimicrob Chemother. 2016; 71(2):513-20.

-Nosrati A, Ch’en PY, Torpey ME, Shokrian N, Ball G, Benesh G, Andriano TM, Zhu TR, Heibel HD, Hosgood HD, Campton KL, Cohen SR. Efficacy and Durability of Intravenous Ertapenem Therapy for Recalcitrant Hidradenitis Suppurativa. JAMA Dermatol. 2024; 160(3):312-318.

-DeFazio MV, Economides JM, King KS, Han KD, Shanmugam VK, Attinger CE, Evans KK. Outcomes after combined radical resection and targeted biologic therapy for the Management of Recalcitrant Hidradenitis Suppurativa. Ann Plast Surg. 2016; 77(2):217-22.

-Bechara FG, Podda M, Prens EP, Horváth B, Giamarellos- Bourboulis EJ, Alavi A, Szepietowski JC, Kirby J, Geng Z, Jean C, Jemec GBE, Zouboulis CC. Efficacy and safety of Adalimumab in conjunction with surgery in moderate to severe hidradenitis Suppurativa: the SHARPS randomized clinical trial. JAMA Surg. 2021; 156(11):1001-9.

-Van Rappard DC, Mekkes JR. Treatment of severe hidradenitis suppurativa with infliximab in combination with surgical interventions. Br J Dermatol. 2012; 167(1):206-8.

-Shanmugam VK, Mulani S, McNish S, Harris S, Buescher T, Amdur R. Longitudinal observational study of hidradenitis suppurativa: impact of surgical intervention with adjunctive biologic therapy. Int J Dermatol. 2018; 57(1):62-9.

-Nawrocki S, Cha J. The etiology, diagnosis, and management of hyperhidrosis: A comprehensive review: Etiology and clinical work-up. J Am Acad Dermatol. 2019; 81(3):657-666.

-Parashar K, Adlam T, Potts G. The Impact of Hyperhidrosis on Quality of Life: A Review of the Literature. Am J Clin Dermatol. 2023; 24(2):187-198.

–Lenefsky M, Rice ZP. Hyperhidrosis and its impact on those living with it. Am J Manag Care. 2018; 24(23 Suppl):S491-S495.

-Delort S, Marchi E, Corrêa MA. Oxybutynin as an alternative treatment for hyperhidrosis. An Bras Dermatol. 2017; 92:217-220.

-Oshima Y, Fujimoto T, Nomoto M, Fukui J, Ikoma A. Hyperhidrosis: A targeted literature review of the disease burden. J Dermatol. 2023; 50(10):1227-1236.

-Henning MAS, Ibler KS, Ostrowski SR, Erikstrup C, Nielsen KR, Bruun MT, Hjalgrim H, Ullum H, Didriksen M, Dinh KM, Rostgaard K, Pedersen OB, Jemec GB. Hyperhidrosis and the risk of being treated for skin infections. J Dermatolog Treat. 2022; 33(4):2263-2269.

-McConaghy JR, Fosselman D. Hyperhidrosis: Management Options. Am Fam Physician. 2018; 97:729-734.

-Schulz V, Ward D, Moulin DE. Segmental hyperhidrosis as a manifestation of spinal and paraspinal disease. Can J Neurol Sci. 1998 Nov;25(4):325-7.

-Slabbynck H, Bedert L, De Deyn PP, Galdermans D, Coolen D. Unilateral segmental hyperhidrosis associated with pulmonary adenocarcinoma. Chest. 1998; 114(4):1215-7.

-Stovner LJ, Sjaastad O. Segmental hyperhidrosis in two siblings with Chiari type I malformation. Eur Neurol. 1995; 35(3):149-55.

-Ohshima Y, Tamada Y. Classification of Systemic and Localized Sweating Disorders. Curr Probl Dermatol. 2016; 51:7-10.

-Lowe N, Naumann M, Eadie N. Treatment of hyperhidrosis with Botox (onabotulinumtoxinA): Development, insights, and impact. Medicine (Baltimore). 2023; 102(S1):e32764.

-Wei Y, Xu ZD, Li H. Quality of life after thoracic sympathectomy for palmar hyperhidrosis: a meta-analysis. Gen Thorac Cardiovasc Surg. 2020 Aug;68(8):746-753.

-Chudry H. The treatment of palmar hyperhidrosis – a systematic review. Int J Dermatol. 2022; 61(11):1303-1310.

-Campanati A, Gregoriou S, Milia-Argyti A, Kontochristopoulos G, Radi G, Diotallevi F, Martina E, Offidani A. The pharmacological treatment and management of hyperhidrosis. Expert Opin Pharmacother. 2022; 23(10):1217-1231.

-Morgado-Carrasco D, de Lucas R. Topical Anticholinergics in the Management of Focal Hyperhidrosis in Adults and Children. A Narrative Review. Actas Dermosifiliogr. 2024; 115(4):356-367.

-Brackenrich J, Fagg C. Hyperhidrosis. 2017 Oct 6. StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2018 Jan-.